Antiplatelets

ApprovedSmall molecule

Pfizer

Antiplatelets is one of 37 small molecule programs targeting Acute Coronary Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

CADASILActive, not recruiting

Acute Coronary SyndromeApproved

Active, not recruiting

CADASILPhase 2

Active, not recruiting

Competition

Competitive Landscape

183 competitors in Acute Coronary Syndrome

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

5 2

Lovenox

Sanofi

Phase 3

4 3

Eliquis

Bristol-Myers Squibb

Phase 3

3 4

Avapro

Sanofi

Phase 3

1 5

Farxiga

AstraZeneca

Phase 3

1 6

Fluzone

Nesina

1 8

Acetylsalicylic Acid

Bayer

Phase 3

5 9

Chantix

PPrism Pharmaceuticals

Phase 3

1 10

Glucophage

EMD Serono

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Coronary Syndrome1 trial

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 4·NCT02984982·206 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT03572972·64,684 enrolled

CADASIL1 trial

Safety Study of Dabigatran in CADASIL

Unknown status·SS. Andrea Hospital·Phase 2·NCT01361763·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Antiplatelets. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiplatelets compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiplatelets. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Antiplatelets

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Coronary Syndrome1 trial

Cohort Study1 trial

CADASIL1 trial

References

Drug Info

Quick Facts

Related News